JP2007528417A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007528417A5 JP2007528417A5 JP2007503030A JP2007503030A JP2007528417A5 JP 2007528417 A5 JP2007528417 A5 JP 2007528417A5 JP 2007503030 A JP2007503030 A JP 2007503030A JP 2007503030 A JP2007503030 A JP 2007503030A JP 2007528417 A5 JP2007528417 A5 JP 2007528417A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- unsubstituted
- ring
- alkyl
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 52
- 125000001072 heteroaryl group Chemical group 0.000 claims 47
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 45
- 125000003118 aryl group Chemical group 0.000 claims 42
- 125000000217 alkyl group Chemical group 0.000 claims 40
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 39
- 125000004404 heteroalkyl group Chemical group 0.000 claims 37
- 229910052739 hydrogen Inorganic materials 0.000 claims 37
- 239000001257 hydrogen Substances 0.000 claims 37
- 150000002431 hydrogen Chemical class 0.000 claims 29
- 229910052757 nitrogen Inorganic materials 0.000 claims 28
- 125000000753 cycloalkyl group Chemical group 0.000 claims 24
- 125000005842 heteroatom Chemical group 0.000 claims 19
- 239000000203 mixture Substances 0.000 claims 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 7
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 7
- 102000003676 Glucocorticoid Receptors Human genes 0.000 claims 6
- 108090000079 Glucocorticoid Receptors Proteins 0.000 claims 6
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims 5
- 125000006582 (C5-C6) heterocycloalkyl group Chemical group 0.000 claims 5
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 150000002367 halogens Chemical class 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 3
- 125000003107 substituted aryl group Chemical group 0.000 claims 3
- 230000003042 antagnostic effect Effects 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 150000002829 nitrogen Chemical group 0.000 claims 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims 2
- 229920006395 saturated elastomer Polymers 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- 125000000547 substituted alkyl group Chemical group 0.000 claims 2
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 125000003710 aryl alkyl group Chemical group 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 125000002541 furyl group Chemical group 0.000 claims 1
- 125000004474 heteroalkylene group Chemical group 0.000 claims 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 125000001786 isothiazolyl group Chemical group 0.000 claims 1
- 125000000842 isoxazolyl group Chemical group 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 125000002971 oxazolyl group Chemical group 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000003373 pyrazinyl group Chemical group 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- 125000000168 pyrrolyl group Chemical group 0.000 claims 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US55183604P | 2004-03-09 | 2004-03-09 | |
| US60/551,836 | 2004-03-09 | ||
| PCT/US2005/008049 WO2005087769A1 (en) | 2004-03-09 | 2005-03-09 | Fused ring azadecalin glucocorticoid receptor modulators |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007528417A JP2007528417A (ja) | 2007-10-11 |
| JP2007528417A5 true JP2007528417A5 (https=) | 2009-07-09 |
| JP4931794B2 JP4931794B2 (ja) | 2012-05-16 |
Family
ID=34961932
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007503030A Expired - Fee Related JP4931794B2 (ja) | 2004-03-09 | 2005-03-09 | 縮合環アザデカリン糖質コルチコイド受容体モジュレーター |
Country Status (17)
| Country | Link |
|---|---|
| US (4) | US7928237B2 (https=) |
| EP (1) | EP1735308B1 (https=) |
| JP (1) | JP4931794B2 (https=) |
| KR (1) | KR101185281B1 (https=) |
| CN (1) | CN101027301B (https=) |
| AT (1) | ATE407934T1 (https=) |
| AU (1) | AU2005222421B2 (https=) |
| CA (1) | CA2558899C (https=) |
| CY (1) | CY1108621T1 (https=) |
| DE (1) | DE602005009687D1 (https=) |
| DK (1) | DK1735308T3 (https=) |
| ES (1) | ES2313317T3 (https=) |
| IL (1) | IL177982A (https=) |
| NZ (1) | NZ550362A (https=) |
| PT (1) | PT1735308E (https=) |
| WO (1) | WO2005087769A1 (https=) |
| ZA (1) | ZA200608306B (https=) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2005222421B2 (en) * | 2004-03-09 | 2010-09-23 | Corcept Therapeutics, Inc. | Fused ring azadecalin glucocorticoid receptor modulators |
| TWI410422B (zh) * | 2007-01-15 | 2013-10-01 | Mitsubishi Tanabe Pharma Corp | 縮合四氫喹啉衍生物及其醫藥用途 |
| EP2532350A1 (en) | 2007-10-17 | 2012-12-12 | Laboratoire HRA Pharma | Pharmaceutical combination of a glucocorticoid receptor antagonist and a cortisol synthesis inhibitor for treating cushing's syndrome |
| US9216221B2 (en) | 2008-11-07 | 2015-12-22 | University Of Sheffield | Medicament and method of diagnosis for treating subclinical Cushing's syndrome |
| ES2531040T3 (es) * | 2009-05-12 | 2015-03-10 | Corcept Therapeutics Inc | Formas sólidas y procedimiento de preparación |
| EP2493303A4 (en) * | 2009-10-30 | 2013-06-26 | Merck Sharp & Dohme | 2- [1-PHENYL-5-HYDROXY-4A-SUBSTITUTED HEXAHYDROCYCLOPENTA [F] INDAZOL-5-YL] ETHYLPHENYL DERIVATIVES AS GLUCOCORTICOID RECEPTOR LIGANDS |
| WO2011087946A1 (en) * | 2010-01-15 | 2011-07-21 | Rigel Pharmaceuticals, Inc. | Screening assay employing dex and gdf8 |
| KR20130106378A (ko) * | 2010-08-27 | 2013-09-27 | 코어셉트 쎄라퓨틱스, 잉크. | 피리딜-아민 융합된 아자데칼린 조절제 |
| US8829024B2 (en) | 2011-01-07 | 2014-09-09 | Corcept Therapeutics, Inc. | Combination steroid and glucocorticoid receptor antagonist therapy |
| US9006568B2 (en) * | 2012-02-15 | 2015-04-14 | Phillips 66 Company | Synthesis of photovoltaic conjugated polymers |
| US20130225633A1 (en) * | 2012-02-27 | 2013-08-29 | Corcept Therapeutics, Inc. | Phenyl heterocycloalkyl glucocorticoid receptor modulators |
| US8859774B2 (en) | 2012-05-25 | 2014-10-14 | Corcept Therapeutics, Inc. | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
| US12226412B2 (en) | 2012-05-25 | 2025-02-18 | Corcept Therapeutics, Inc. | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
| PT4119561T (pt) * | 2012-05-25 | 2024-09-30 | Corcept Therapeutics Inc | Moduladores de recetores de glucocorticoides de azadecalina fundida com heteroaril-cetona |
| US9691986B2 (en) | 2012-12-03 | 2017-06-27 | Solarmer Energy, Inc. | Furan and selenophene derivatized benzo [1,2-b:4,5-b′] dithiophene-thienothiophene based conjugated polymers for high-efficiency organic solar cells |
| FI3848027T3 (fi) * | 2013-11-25 | 2023-05-04 | Corcept Therapeutics Inc | Oktahydrofuusioituja atsadekaliiniglukokortikoidireseptorin modulaattoreita |
| WO2015077537A1 (en) * | 2013-11-25 | 2015-05-28 | Corcept Therapeutics, Inc. | Heteroaryl-ether fused azadecalin glucocorticoid receptor modulators |
| CN107530435A (zh) * | 2015-03-02 | 2018-01-02 | 科赛普特治疗学股份有限公司 | 使用糖皮质激素受体拮抗剂和生长抑素治疗acth分泌型肿瘤 |
| WO2016160969A1 (en) | 2015-03-30 | 2016-10-06 | Corcept Therapeutics, Inc. | Use of glucocorticoid receptor antagonists in combination with glucocorticoids to treat adrenal insufficiency |
| ES2865334T3 (es) | 2015-08-13 | 2021-10-15 | Corcept Therapeutics Inc | Método de diagnóstico diferencial de síndrome de Cushing dependiente de ACTH |
| US10312448B2 (en) | 2015-10-01 | 2019-06-04 | Phillips 66 Company | Process of manufacturing an electron transport material |
| US9905769B2 (en) | 2015-10-01 | 2018-02-27 | Phillips 66 Company | Process of manufacturing an electron transport material |
| WO2017058406A1 (en) | 2015-10-01 | 2017-04-06 | Phillips 66 Company | Formation of films for organic photovoltaics |
| US9911919B2 (en) | 2015-10-01 | 2018-03-06 | Phillips 66 Company | Process of manufacturing an electron transport material |
| US10418555B2 (en) | 2015-10-01 | 2019-09-17 | Phillips 66 Company | Formation of films for organic photovoltaics |
| CA3011728A1 (en) | 2016-01-19 | 2017-07-27 | Corcept Therapeutics, Inc. | Differential diagnosis of ectopic cushing's syndrome |
| IL297201A (en) | 2016-03-01 | 2022-12-01 | Corcept Therapeutics Inc | Use of glucocorticoid receptor modulators to increase the activity of checkpoint inhibitors |
| US9943505B2 (en) | 2016-09-09 | 2018-04-17 | Corcept Therapeutics, Inc. | Glucocorticoid receptor modulators to treat pancreatic cancer |
| JP7564620B2 (ja) | 2017-03-09 | 2024-10-09 | コーセプト セラピューティクス， インコーポレイテッド | カテコールアミン分泌腫瘍の処置における糖質コルチイド受容体モジレータの使用 |
| CA3055076C (en) | 2017-03-31 | 2022-02-22 | Corcept Therapeutics, Inc. | Glucocorticoid receptor modulators to treat cervical cancer |
| AU2018289307B2 (en) | 2017-06-20 | 2024-02-01 | Corcept Therapeutics, Inc. | Methods of treating neuroepithelial tumors using selective glucocorticoid receptor modulators |
| IL263184A (en) | 2018-11-21 | 2020-05-31 | Yarden Yosef | Method of treating cancer and compositions for same |
| WO2020132046A1 (en) | 2018-12-19 | 2020-06-25 | Corcept Therapeutics Incorporated | Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent |
| US11234971B2 (en) | 2018-12-19 | 2022-02-01 | Corcept Therapeutics Incorporated | Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent |
| FI3897589T3 (fi) | 2018-12-19 | 2026-01-13 | Corcept Therapeutics Inc | Farmaseuttisia formulaatioita, jotka sisältävät relakorilanttia, heteroaryyliketonifusoitua atsekaliiniyhdistettä |
| JP7789561B2 (ja) | 2019-02-22 | 2025-12-22 | コーセプト セラピューティクス， インコーポレイテッド | レラコリラント、ヘテロアリール－ケトン縮合アザデカリングルココルチコイド受容体調節物質の治療用途 |
| AU2020239920A1 (en) | 2019-03-18 | 2021-11-04 | Arnold L. Newman | Method of improving insulin sensitivity |
| WO2021076565A1 (en) | 2019-10-16 | 2021-04-22 | Corcept Therapeutics Incorporated | Method of normalizing the neutrophil to lymphocyte ratio in cancer patients with a selective glucocorticoid receptor antagonist |
| PH12022551430A1 (en) | 2019-12-11 | 2023-11-20 | Corcept Therapeutics Inc | Methods of treating antipsychotic-induced weight gain with miricorilant |
| US20230358768A1 (en) | 2019-12-21 | 2023-11-09 | Corcept Therapeutics Incorporated | Treatment of, and differential diagnosis between, acth-dependent cushing's syndrome and acth-independent cushing's syndrome |
| BR112022015011A2 (pt) | 2020-01-29 | 2022-09-20 | Corcept Therapeutics Inc | Método para tratar um sujeito que sofre de tumor de carcinoma adrenocortical e tendo excesso de cortisol, e, composição farmacêutica para tratar carcinoma adrenocortical |
| CA3166901A1 (en) * | 2020-02-10 | 2021-08-19 | Corcept Therapeutics Incorporated | Methods of stimulating an anti-tumor response using a selective glucocorticoid receptor modulator |
| US11285145B2 (en) | 2020-05-27 | 2022-03-29 | Corcept Therapeutics Incorporated | Concomitant administration of glucocorticoid receptor modulator relacorilant and paclitaxel, a dual substrate of CYP2C8 and CYP3A4 |
| AU2021296163B2 (en) | 2020-06-22 | 2024-07-04 | Corcept Therapeutics Incorporated | Quaternary indazole glucocorticoid receptor antagonists |
| WO2022081725A1 (en) * | 2020-10-16 | 2022-04-21 | The Scripps Research Institute | Therapeutic uses of glucocorticoids with anabolic effects in skeletal muscle |
| WO2022134033A1 (en) | 2020-12-25 | 2022-06-30 | Corcept Therapeutics Incorporated | Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
| WO2022166810A1 (zh) * | 2021-02-03 | 2022-08-11 | 江苏恒瑞医药股份有限公司 | 稠合的氮杂三环类衍生物、其制备方法及其在医药上的应用 |
| CN114907340A (zh) * | 2021-02-09 | 2022-08-16 | 江苏恒瑞医药股份有限公司 | 稠合的氮杂三环类衍生物、其制备方法及其在医药上的应用 |
| IL313663A (en) | 2021-12-21 | 2024-08-01 | Corcept Therapeutics Inc | Piperazine indazole glucocorticoid receptor antagonists |
| KR20240125035A (ko) | 2021-12-21 | 2024-08-19 | 코어셉트 쎄라퓨틱스 인코포레이티드 | 이환 인다졸 글루코코르티코이드 수용체 길항제 |
| AU2023301396A1 (en) * | 2022-06-28 | 2024-12-12 | Corcept Therapeutics Incorporated | Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
| CN117510490A (zh) * | 2022-08-03 | 2024-02-06 | 江苏恒瑞医药股份有限公司 | 一种稠合氮杂萘烷类衍生物的晶型及其制备方法 |
| IL319657A (en) | 2022-10-06 | 2025-05-01 | Corcept Therapeutics Inc | Glucocorticoid receptor modulator formulations |
| WO2024092195A1 (en) | 2022-10-28 | 2024-05-02 | Corcept Therapeutics Incorporated | Treatments for amyotrophic lateral sclerosis using dazucorilant |
| CN120787227A (zh) * | 2023-02-24 | 2025-10-14 | 科赛普特治疗公司 | 制备杂芳基-酮稠合的氮杂萘烷糖皮质激素受体调节剂的中间体的方法 |
| WO2025152964A1 (en) * | 2024-01-15 | 2025-07-24 | Insilico Medicine Ip Limited | Novel compounds as glucocorticoid receptor modulators and uses thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8828669D0 (en) * | 1988-12-08 | 1989-01-11 | Lilly Industries Ltd | Organic compounds |
| EP1512683B1 (en) * | 1998-03-10 | 2011-08-31 | Research Triangle Institute | Novel opiate compounds, methods of making and methods of use |
| GB9911053D0 (en) * | 1999-05-12 | 1999-07-14 | Pharmacia & Upjohn Spa | 4,5,6,7-tetrahydroindazole derivatives process for their preparation and their use as antitumour agents |
| CA2473886C (en) * | 2002-01-22 | 2012-08-21 | The Regents Of The University Of California | Non-steroidal ligands for the glucocorticoid receptor, compositions and uses thereof |
| AU2005222421B2 (en) * | 2004-03-09 | 2010-09-23 | Corcept Therapeutics, Inc. | Fused ring azadecalin glucocorticoid receptor modulators |
| ES2531040T3 (es) * | 2009-05-12 | 2015-03-10 | Corcept Therapeutics Inc | Formas sólidas y procedimiento de preparación |
-
2005
- 2005-03-09 AU AU2005222421A patent/AU2005222421B2/en not_active Ceased
- 2005-03-09 AT AT05725295T patent/ATE407934T1/de active
- 2005-03-09 KR KR1020067020988A patent/KR101185281B1/ko not_active Expired - Fee Related
- 2005-03-09 CA CA2558899A patent/CA2558899C/en not_active Expired - Lifetime
- 2005-03-09 DK DK05725295T patent/DK1735308T3/da active
- 2005-03-09 JP JP2007503030A patent/JP4931794B2/ja not_active Expired - Fee Related
- 2005-03-09 PT PT05725295T patent/PT1735308E/pt unknown
- 2005-03-09 DE DE602005009687T patent/DE602005009687D1/de not_active Expired - Lifetime
- 2005-03-09 ES ES05725295T patent/ES2313317T3/es not_active Expired - Lifetime
- 2005-03-09 WO PCT/US2005/008049 patent/WO2005087769A1/en not_active Ceased
- 2005-03-09 US US10/591,884 patent/US7928237B2/en active Active
- 2005-03-09 NZ NZ550362A patent/NZ550362A/en not_active IP Right Cessation
- 2005-03-09 EP EP05725295A patent/EP1735308B1/en not_active Expired - Lifetime
- 2005-03-09 CN CN2005800114815A patent/CN101027301B/zh not_active Expired - Fee Related
-
2006
- 2006-09-10 IL IL177982A patent/IL177982A/en active IP Right Grant
- 2006-10-05 ZA ZA200608306A patent/ZA200608306B/xx unknown
-
2008
- 2008-12-05 CY CY20081101413T patent/CY1108621T1/el unknown
-
2011
- 2011-03-11 US US13/046,529 patent/US20110166110A1/en not_active Abandoned
-
2012
- 2012-05-21 US US13/476,776 patent/US8557839B2/en not_active Expired - Fee Related
-
2013
- 2013-09-12 US US14/025,459 patent/US20140179671A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007528417A5 (https=) | ||
| JP2008505117A5 (https=) | ||
| HRP20200549T1 (hr) | Određeni amino-pirimidini, njihovi sastavi, i metode njihove upotrebe | |
| JP2006515858A5 (https=) | ||
| JP2007534695A5 (https=) | ||
| JP2022506887A5 (https=) | ||
| JP2005504789A5 (https=) | ||
| JP2020536881A5 (https=) | ||
| JP2022512588A5 (https=) | ||
| JP2015506347A5 (https=) | ||
| JP2006511563A5 (https=) | ||
| KR950003275A (ko) | 1-벤젠술포닐-1, 3-디히드로-2h-벤즈이미다졸-2-온 유도체 | |
| JP2004529874A5 (https=) | ||
| JP2007524696A5 (https=) | ||
| JP2013504593A5 (https=) | ||
| RU2006112593A (ru) | Производные 2, 4-ди(гетеро)ариламинопиримидина в качестве ингибиторов zap-70 и/или syk | |
| JP2006524222A5 (https=) | ||
| EP1612208B1 (en) | N-phenylarylsulfonamide compound, pharmaceutical composition comprising the compound as active ingredient, synthetic intermediate for the compound and process for its preparation | |
| JPH034069B2 (https=) | ||
| JP2020535165A5 (https=) | ||
| JP2020511547A5 (https=) | ||
| RU2007108863A (ru) | Производные пиразола для лечения состояний, опосредованных активацией рецептора аденозина а2в или а3 | |
| JP2006509842A5 (https=) | ||
| JP2007517895A5 (https=) | ||
| DE4341665A1 (de) | Bicyclen-Derivate, ihre Herstellung und Verwendung |